Investigators prospectively evaluated the efficacy, general safety, and joint safety of fasinumab in patients with hip and/or knee pain in osteoarthritis.
The incidence of secondary hip procedures does not differ for independently ambulating patients with displaced femoral neck fractures who undergo total hip arthroplasty or hemiarthroplasty.
The levels of urine C-telopeptide of cross-linked collagen type II were found to be independently associated with pain intensity and radiographic severity in patients with osteoarthritis.
Researchers sought to identify autoantibodies in serum that could be useful in predicting incidence of radiographic knee osteoarthritis.
Researchers evaluated the predictive factors that could contribute to hip osteoarthritis progression.
Future longitudinal studies are needed to explore causal relationships between first carpometacarpal (CMC-1) inflammation and pain, and clinical trials are needed that have a low risk for bias and examine the efficacy of anti-inflammatory treatment in inflamed CMC-1 joints.
Investigators examined the relationship between nonsteroidal anti-inflammatory drugs and the risk for cardiovascular disease among patients with osteoarthritis.
It may be possible to identify persons at risk for suffering a worsening in health-related quality of life (HRQoL) due to knee osteoarthritis.
Researchers set out to identify a threshold for activity in adults with lower extremity joint symptoms. We review their findings.
Osteoarthritis is an independent risk factor for increased CVD, and NSAIDs contribute substantially to this risk.